A Molecular Docking Study Reveals That Short Peptides Induce Conformational Changes in the Structure of Human Tubulin

Oluwakemi Ebenezer1,2, Nkululeko Damoyi1, Michael Shapi1

  • 1Department of Chemistry, Faculty of Natural Science, Mangosuthu University of Technology, Umlazi 4031, South Africa.

Insights

Computational screening identified short peptides that inhibit tubulin polymerization, offering potential new anticancer drugs to overcome chemotherapy resistance. Further research is needed for validation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Microtubules, formed by αβ tubulin dimers, are crucial for cell division and proliferation, making them key targets for anticancer drugs.
  • Tumor cells often develop drug resistance, limiting the effectiveness of current chemotherapy and necessitating the development of novel therapeutics.

Purpose of the Study:

  • To computationally screen antimicrobial peptides for their potential to inhibit tubulin polymerization.
  • To identify novel peptide candidates for anticancer drug development that can overcome drug resistance.

Main Methods:

  • Retrieved short peptides from the Antimicrobial Peptide Database (DRAMP).
  • Utilized multiple docking programs (PATCHDOCK, FIREDOCK, ClusPro) to predict tertiary structures and binding affinities.
  • Performed molecular dynamics simulations to confirm the stability of peptide-tubulin complexes.
  • Conducted physiochemical toxicity and allergenicity assessments.

Main Results:

  • Docking analysis revealed that selected peptides bind to the interface residues of tubulin isoforms (αβI, αβII, αβIII, αβIV).
  • Molecular dynamics simulations confirmed stable interactions between the identified peptides and tubulin.
  • Toxicity and allergenicity studies provided initial safety assessments for the candidate peptides.

Conclusions:

  • The identified peptides show potential to destabilize tubulin polymerization, suggesting their utility as novel anticancer agents.
  • These peptides represent promising candidates for further development into drugs to combat cancer, particularly in cases of drug resistance.
  • Experimental validation is required to confirm the therapeutic efficacy of these peptide candidates.